Detalhe da pesquisa
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256976
2.
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 566(7745): E11-E12, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755741
3.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37633306
4.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37387213
5.
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature
; 554(7691): 189-194, 2018 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420467
6.
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Breast Cancer Res Treat
; 197(2): 319-331, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36401732
7.
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.
Breast Cancer Res Treat
; 188(2): 415-425, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34109515
8.
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
Cancer
; 126(22): 4967-4974, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32809222
9.
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Breast Cancer Res Treat
; 183(1): 227-237, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32613539
10.
Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT.
Radiology
; 296(2): 370-378, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32515679
11.
How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Ann Surg Oncol
; 27(12): 4702-4710, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32839900
12.
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
Breast Cancer Res Treat
; 168(1): 57-67, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29124456
13.
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
Breast Cancer Res
; 19(1): 89, 2017 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28764748
14.
Voxelwise analysis of simultaneously acquired and spatially correlated 18 F-fluorodeoxyglucose (FDG)-PET and intravoxel incoherent motion metrics in breast cancer.
Magn Reson Med
; 78(3): 1147-1156, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27779790
15.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Invest New Drugs
; 35(6): 742-750, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28281183
16.
Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Radiology
; 281(1): 193-202, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27023002
17.
Current Status of Hybrid PET/MRI in Oncologic Imaging.
AJR Am J Roentgenol
; 206(1): 162-72, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26491894
18.
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
Breast Cancer Res
; 16(2): R32, 2014 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24684785
19.
Genome-based risk prediction for early stage breast cancer.
Oncologist
; 19(10): 1019-27, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25187476
20.
Pertuzumab in the treatment of HER2+ breast cancer.
J Natl Compr Canc Netw
; 12(4): 591-8, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24717573